hCG therapy for the treatment of breast cancer
View Patent ↗This invention relates to the field of cancer therapy. More particularly, the invention relates to the treatment of mammary tumor, clinically manifest mammary tumor (breast cancer) and metastatic mammary tumor by administration of human Chorionic Gonadotropin (hCG). The treatment preferably comprises the administration of hCG in conjunction with an antiestrogen and/or a Type I Interferon.
1. A method of treating metastatic mammary tumors in postmenopausal women, comprising the steps of:
a) detecting a metastatic mammary tumor in a postmenopausal woman;
b) administering to the postmenopausal woman a first dose of hCG; and
c) administering to the postmenopausal woman one or more subsequent doses of hCG, wherein the first dose and the subsequent doses of hCG are administered in an amount and over a period of time effective to inhibit proliferation of mammary tumor cells, thereby treating the metastatic mammary tumors.
2. The method of claim 1 , combined with at least one other treatment for metastatic mammary tumors.
3. The method of claim 2 , wherein the at least one other treatment is surgery or chemotherapy.
4. The method of claim 1 , wherein the mammary tumors comprise cells that are estrogen receptor-positive.
5. The method of claim 1 , wherein the hCG is administered in an amount of 100 to 20,000 IU per day.
6. The method of claim 1 , wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.
7. The method of claim 6 , wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.
8. The method of claim 1 , wherein the one or more subsequent doses of hCG are administered every second day following administration of the first dose.
9. The method of claim 1 , wherein the one or more subsequent doses of hCG are administered three times each week following administration of the first dose.
10. The method of claim 1 , wherein the one or more subsequent doses of hCG are administered for several weeks following administration of the first dose.
11. The method of claim 10 , wherein the hCG is administered for at least 12 weeks.
12. The method of claim 1 , wherein the hCG is administered subcutaneously.
13. The method of claim 1 , wherein the hCG is administered in combination with Type 1 interferon.
14. The method of claim 1 , wherein the hCG is recombinant hCG.